Company intelligence / Profile preview

Aviir

Irvine, California, United Statesaviir.net ↗

Ownership: Private
Development stage: Other

Overview

Aviir developed and commercialized laboratory-based diagnostic tests to assess individual risk for cardiovascular events, particularly heart attacks, using proprietary biomarker panels analyzed via blood samples. Their MIRISK VP™ and TruRisk™ platforms combined protein biomarker measurement with algorithmic analysis to provide five-year cardiac event risk predictions. The company also offered a broader menu of cardiovascular and metabolic tests through its CLIA-certified lab.

Therapeutic areas: Metabolic DisordersCardiovascular
Modalities: Diagnostic testBiomarker immunoassayGenomic analysisTranscription analysis
Industry: Protein Biomarker Diagnostics

Partnerships

Merck Global Health Innovation Fund (lead investor in a major round)

Beyond the preview

Go deeper on Aviir.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aviir.

Explore the full profile